EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma

Zhenzhen Hao, Fei An, Wanting Zhang, Xiaoshuang Zhu, Shihao Meng, Bo Zhao

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26052061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Zhenzhen Hao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Molecular Biology, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Protein Serine-Threonine Kinases, Biomarkers, Tumor, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BUB1B, a member of the spindle assembly checkpoint family known as BUB1 mitotic checkpoint serine/threonine kinase B, has been associated with the promotion of tumor progression. Nevertheless, its specific contributions to tumorigenesis remain largely unexplored. This study seeks to offer a systematic and comprehensive analysis of the role of BUB1B in the progression of various cancers, with a particular focus on lung adenocarcinoma, utilizing a range of databases. We investigated BUB1B’s role in pan-cancer using TCGA data, analyzing it with platforms like HPA, TIMER, TISIDB, GEPIA, cBioPortal, GDC, LinkedOmics, and CancerSEA. Additionally, we assessed BUB1B’s impact on lung adenocarcinoma proliferation and migration through CCK-8, wound healing, transwell assays and Western blot analysis. This study found that BUB1B was upregulated in most cancers and was significantly linked to patient prognosis. Its expression correlated with immune cell infiltration and genetic markers of immunomodulators across different cancers. BUB1B was involved in the acute inflammatory response and IgA production pathways but negatively correlated with inflammation in lung adenocarcinoma. Moreover, the siRNA-mediated knockdown of BUB1B resulted in the inhibition of proliferation and migration of lung cancer cells in vitro. This study underscores the potential of BUB1B as a biomarker and a promising therapeutic target for patients with lung adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungProtein Serine-Threonine KinasesBiomarkers, TumorLung NeoplasmsCell Cycle ProteinsHumansPrognosisCell ProliferationCell MovementGene Expression Regulation, NeoplasticCell Line, Tumor

Stichwörter der Autor:innen

BUB1BLUADbiomarkerimmune microenvironmentpan-cancerprognosis

Substanzen

Protein Serine-Threonine KinasesBiomarkers, TumorBUB1B protein, humanCell Cycle Proteins

Autor:innen und Institutionen

  • Institute of Biochemistry and Molecular Biology, College of Life and Health Sciences, Northeastern University, Shenyang 110819, China.

Förderung

  • Natural Science Foundation of Liaoning Province

Zitieren

APA

Hao, Z., An, F., Zhang, W., Zhu, X., Meng, S., & Zhao, B. (2025). A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052061

Vancouver

Hao Z, An F, Zhang W, Zhu X, Meng S, Zhao B. A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052061

BibTeX
@article{Hao2025,
  author = {Hao, Zhenzhen and An, Fei and Zhang, Wanting and Zhu, Xiaoshuang and Meng, Shihao and Zhao, Bo},
  title = {A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26052061}
}
Kostenlos starten →